大剂量重组人血管内皮抑素对肺癌转移瘤的实验研究

Effects of recombinant human endostatin(endostar) on the growth of lung cancer metastasis

目的探讨大剂量重组人血管内皮抑素(恩度)单药对肺癌的作用。方法建立肺癌裸鼠转移瘤模型,检测腹腔给药和皮下注射两种途径恩度(50mg/kg)在实验SD大鼠中的血药浓度,同时分别设生理盐水对照组和恩度10、20、50、100、200mg/(kg.d)组,观察小鼠的生存情况,计算生存期以及肺部转移灶数量。结果恩度腹腔给药和皮下注射两种途径药代动力学相似,半衰期约为24h。100mg/(kg.d)恩度组小鼠的中位生存期达61天,较对照组延长10天。小鼠肺部转移病灶数量与恩度剂量有一定相关性,100mg/(kg.d)恩度组转移灶数量最少,与对照组比较有统计学上显著差异(P<0.05)。结论在肺癌转移瘤模型中,大剂量恩度能够有效地抑制肺癌的生长,生存期延长,生存质量较好。

Objective This experiment was to identify the effect of recombinant human endostatin （endostar） on the growth of lung cancer in nude mouse. Methods A nude mouse mode with lung metastasis was established. Each group of mice was treated with high dose of endostar： 10mg/（kg·d） ,20mg/（kg·d） , 50mg/（kg·d） , 100mg/（kg·d）, 200mg/（kg·d） as well as a control group. Observe the living condition of the mice ; calculate survival time and number of metastasis on the lung. Results The median survival time of 100mg/（ kg·d）group was 61 days, which was lO days longer than the control group. Compared to the control group, a connection between the number of metastasis and dose was observed. The 100mg/（kg·d） group also has the least metastasis compared with control group（ P 〈 0. 05 ）. Conclusion High dose of endostar has the ability to inhibit the growth of lung cancer metastasis, is able to prolong the survival time.